Domo signs strategic collaboration agreement with AWS for AI solutions
CONSHOHOCKEN, PA—Cencora, Inc. (NYSE:COR), a $51.6 billion market cap healthcare services company, saw its President and CEO Robert Mauch execute significant stock transactions, according to a recent SEC filing. On March 18, Mauch sold a total of 4,970 shares of Cencora’s common stock at a price of $260.93 per share, amounting to approximately $1.3 million. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024. The stock has shown strong momentum, trading near its 52-week high with a 17.8% return year-to-date.
Additionally, Mauch exercised options to acquire 3,226 shares at $86.09 per share, bringing the total cost of the acquisition to $277,726. Following these transactions, Mauch holds 49,326 shares of the company directly. InvestingPro analysis shows Cencora maintains a "GOOD" financial health score, though it trades at a relatively high P/E ratio of 37.6x.
These moves are part of a broader strategy by the executive, reflecting both the exercise of stock options and the strategic sale of shares. Investors will be watching closely to see how these transactions impact Cencora’s stock performance on the New York Stock Exchange. For deeper insights into Cencora’s valuation and 12+ additional exclusive ProTips, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Cencora, Inc. has made significant strides with its financial and strategic initiatives. The company completed the acquisition of Retina Consultants of America for $4.4 billion, leading to an upward revision of its fiscal year 2025 adjusted earnings per share (EPS) guidance. Cencora now expects an EPS range of $15.15 to $15.45, up from the previous estimate of $14.80 to $15.10. Additionally, Leerink Partners has raised Cencora’s stock price target to $301, maintaining an Outperform rating, following the company’s strong first-quarter results and solid performance in the U.S. Healthcare sector.
In terms of governance, Cencora held its Annual Meeting where shareholders approved executive compensation and elected directors, with all nominated board members confirmed. Furthermore, Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2025. Meanwhile, the company announced that board members Richard W. Gochnauer and Kathleen W. Hyle will retire at the next Annual Meeting, leading to a reduction in board size from 13 to 11 members. These developments highlight Cencora’s strategic focus on growth and governance as it continues to navigate the healthcare landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.